Answers are grounded in this paper and cite their sources.
KAT6A and KAT7 associate with NUP98 FOs to drive leukemogenesis. Inhibition of their HAT activity is an effective therapeutic strategy in NUP98-r leukemias, including those resistant to menin inhibition. Moreover, combined KAT6A/7 and menin inhibition is synergistic, supporting clinical translation to improve outcomes for NUP98 FO-driven leukemias.
No takes yet. Share an insight, caveat, or question.
Michmerhuizen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: